Novo Nordisk A/S (NVO) earnings: date, estimates, results and stock reactions
Next earnings: Q1 FY2028 on 2027-02-03 (expected, before the open). EPS estimate 4.51, revenue estimate 78.76B.
Over the last 12 reports the stock moved 3.9% on average (either way), rising 5 times and falling 7. EPS beat estimates 10 of 12 times; revenue 9 of 12. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).
| Quarter | Reported | EPS | EPS estimate | EPS surprise | Revenue | Revenue estimate | Stock move |
|---|---|---|---|---|---|---|---|
| Q4 FY2027 | 2026-11-04 | 5.79 | 4.80 | +20.6% | 80.00B | 73.65B | +0.4% |
| Q3 FY2027 | 2026-08-05 | 6.10 | 5.03 | +21.3% | 77.42B | 71.35B | -4.6% |
| Q2 FY2027 | 2026-05-06 | 6.48 | 5.88 | +10.2% | 68.66B | 69.62B | +3.4% |
| Q1 FY2027 | 2026-02-03 | 6.04 | 5.87 | +2.9% | 78.42B | 76.91B | -18.3% |
| Q4 FY2026 | 2025-11-05 | 4.50 | 4.97 | -9.5% | 76.05B | 76.53B | -2.6% |
| Q3 FY2026 | 2025-08-06 | 6.00 | 5.98 | +0.3% | 77.41B | 76.95B | +1.0% |
| Q2 FY2026 | 2025-05-07 | 6.53 | 5.88 | +11.1% | 78.09B | 77.94B | -2.8% |
| Q1 FY2026 | 2025-02-04 | 6.35 | 6.16 | +3.1% | 85.80B | 80.14B | +3.3% |